Skip to content
    ARCH Venture Partners logo

    ARCH Venture Partners

    Chicago, Illinois, United StatesFounded 1986
    www.archventure.comLinkedIn
    Biotech & Life SciencesHealthcareHardware & Semiconductors

    ARCH Venture Partners is a venture capital firm founded in 1986 and headquartered in Chicago. The firm invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on life sciences, biotechnology, and physical sciences to prevent, detect, and cure disease.

    52% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $181.4M (across 328 rounds with reported amounts).

    Find people at ARCH Venture Partners on Goldilocks AI

    Portfolio

    220

    Fund Size

    $3B

    Top Stage

    Series B

    Last 12 Mo

    22

    Team

    CB

    Clinton Bybee

    Co-founder & Managing Director, Emeritus

    KC

    Keith Crandell

    Co-founder & Managing Director

    RN

    Robert Nelsen

    Co-founder & Managing Director

    SL

    Steve Lazarus

    Co-Founder & Managing Director (1931-2018)

    KB

    Kristina Burow

    Managing Director

    MM

    Mark McDonnell

    Managing Director, CFO & CAO

    PB

    Paul Berns

    Managing Director

    PT

    Paul Thurk

    Managing Director (1970-2021)

    BC

    Brian Cuneo

    Senior Partner

    CS

    Carol Suh

    Partner

    CR

    Corey Ritter

    Partner

    DM

    David Moore

    Senior Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    357 investments
    CompanyRoundAmountDate
    Treeline Biosciences logoTreeline BiosciencesSeries A$200MSep 2026
    PParabilisSeries F$305MSep 2026
    Encoded Therapeutics logoEncoded TherapeuticsSeries F$275MSep 2026
    LLifeMineSeries E$188MAug 2026
    Trase logoTraseSeed$107MJun 2026
    OOllinSeries B$330MJun 2026
    Prometheus logoPrometheusSeries B$12BJun 2026
    City Therapeutics logoCity TherapeuticsSeries B$99.5MJun 2026
    Create Medicines logoCreate MedicinesSeries B$122MMay 2026
    Moleculent AB logoMoleculent ABUnknown$20MApr 2026
    Mirador logoMiradorSeries B$250MJan 2026
    Mirador Tx logoMirador TxSeries B$250MJan 2026
    Vizgen logoVizgenSeries C$48MJan 2026
    Parabilis Medicines logoParabilis MedicinesSeries F$305MJan 2026
    City Therapeutics logoCity TherapeuticsUnknown$99.5MJan 2026
    Create Medicines logoCreate MedicinesSeries B$122MJan 2026
    Enumerix logoEnumerixUnknown$26MJan 2026
    Ollin Biosciences logoOllin BiosciencesSeries B$330MJan 2026
    Lightcast logoLightcastUnknown$27MJan 2026
    SSalma HealthSeries A$80MJan 2026
    Encoded Therapeutics logoEncoded TherapeuticsSeries F$275MJan 2026
    Metsera logoMetseraSeries B$215MJan 2026
    Prometheus logoPrometheusSeries B$12BJan 2026
    PParabilisSeries F$305MJan 2026
    EEncodedSeries F$275MJan 2026
    Page 1 of 15

    Top Co-Investors

    Alexandria Venture Investments62 shared
    GV61 shared
    F-Prime Capital39 shared
    Polaris Partners38 shared
    The Invus Group, LLC27 shared
    General Catalyst26 shared
    Fidelity Investments25 shared
    Fidelity Management & Research Company23 shared
    Mubadala Ventures21 shared
    Primary Venture Partners20 shared
    Foresite Capital20 shared
    T. Rowe Price20 shared
    Moore Strategic Ventures18 shared
    Altitude Life Science Ventures18 shared
    Flagship Pioneering17 shared
    Newpath Partners17 shared
    Illumina Ventures17 shared
    Cormorant Asset Management17 shared
    Third Rock Ventures17 shared
    Casdin Capital16 shared

    Last updated: 7 October 2026